Scholar Rock Holding (SRRK) Total Non-Current Liabilities (2017 - 2021)
Scholar Rock Holding's (SRRK) quarterly Total Non-Current Liabilities came in at $115.4 million in Q2 2021, down 3.87% quarter-over-quarter from $120.0 million in Q1 2021.
Scholar Rock Holding (SRRK) Total Non-Current Liabilities (2017 - 2021) Analysis & Trends
Scholar Rock Holding's Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $115.4 million for Q2 2021.
- On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $115.4 million in Q2 2021; TTM through Jun 2021 was $115.4 million, a N/A change from a year earlier, with the FY2020 full-year figure at $127.5 million, up 52.78% from the prior year.
- Total Non-Current Liabilities fell to $115.4 million in Q2 2021 per SRRK's latest filing, from $120.0 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $127.5 million in Q4 2020 and bottomed at $5.9 million in Q4 2017.
- The 4-year median for Total Non-Current Liabilities is $115.4 million (2021), against an average of $90.5 million.
- Biggest YoY gain for Total Non-Current Liabilities was 52.78% in 2020; the steepest drop was 52.78% in 2020.
- Year by year, Total Non-Current Liabilities stood at $5.9 million in 2017, then soared by 1317.16% to $83.5 million in 2019, then jumped by 52.78% to $127.5 million in 2020, then fell by 9.52% to $115.4 million in 2021.
- Per Business Quant, the three latest SRRK Total Non-Current Liabilities figures stand at $115.4 million (Q2 2021), $120.0 million (Q1 2021), and $127.5 million (Q4 2020).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 115.39 Mn |
| Mar 31, 2021 | 120.04 Mn |
| Dec 31, 2020 | 127.53 Mn |
| Dec 31, 2019 | 83.47 Mn |
| Dec 31, 2017 | 5.89 Mn |